LDPath
LDPath is a UK-based digital pathology reporting service, owned by Source BioScience, providing whole slide imaging and AI-assisted histopathology to 24 NHS trusts and 450+ private clinicians via a network of 140 specialist pathologists.
- Company typePrivate
- Founded2011
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What LDPath does
LDPath is a UK-based digital pathology reporting service founded in 2011, headquartered in Chichester with operations in London, and operating as a subsidiary of Source BioScience following a 2021 acquisition for £18.5 million. The company provides histopathology reporting services to 24 NHS trusts and 450+ private clinicians and clinics, utilizing a network of approximately 140 specialist consultant pathologists (over 100 of whom are validated on Whole Slide Imaging for primary diagnosis). LDPath was the first UK pathology provider to integrate whole slide imaging into primary reporting (2014) and the first to deploy clinical-grade AI for cancer detection through a 2020 partnership with Ibex Medical Analytics (CE-Marked Galen Prostate solution), and has accumulated over 100TB of digital pathology slides — described as the largest such library in the UK.
The company's core technology stack combines a proprietary, pathologist-designed LIMS application with whole slide imaging infrastructure, NHS HSCN connectivity, and AI-powered diagnostic modules, supporting a 1–2 day histology report turnaround with 94% of cases reported within 72 hours (sustained since 2014). Service modules include NHS Pathology Services, Private Practice Services, AI-Powered Diagnostics (Ibex Galen Prostate), Diagnostic Audits, and standalone Whole Slide Imaging scanning. The platform is held together by UKAS, ISO 9001, ISO 15189, CQC, and NHS Digital DSP Toolkit accreditations, plus sole registration in the National NHS Procurement Directory.
LDPath generates revenue through multi-year, flat-fee service contracts with NHS trusts and private practices on a per-case subscription basis, supplemented by professional services revenue from AI diagnostic workflows, standalone WSI scanning, and independent diagnostic audits. The go-to-market motion is enterprise field sales via dedicated NHS and Private Practice department managers supported by a UK-wide medical courier specimen collection network. International operations have been established via LDPath India and LDPath Dubai, extending digital pathology services into South Asian and Middle Eastern markets.
LDPath firmographics
Firmographics- Name
- LDPath
- Legal name
- LDPath
- Website
- https://ldpath.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- LDPath is a UK-based digital pathology reporting service, owned by Source BioScience, providing whole slide imaging and AI-assisted histopathology to 24 NHS trusts and 450+ private clinicians via a network of 140 specialist pathologists.
- Ownership category
- akta.pro rank
LDPath industry classification
Industry- Product category
- Digital Pathology Services
- NAICS
- Diagnostic Imaging Centers (621512)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Pathology & Histopathology Services (HLAGAFAI)
- akta.pro secondary industries
- Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB), Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where LDPath is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
LDPath business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Histopathology Reporting Services: LDPath provides rapid histopathology reporting by specialist pathologists to NHS trusts and private practices. Services include specimen pickup, processing, diagnosis, and secure web-based report delivery. Turnaround time of 1-2 days for histology reports.
- AI Diagnostic Services: AI-powered cancer detection services including primary reporting of prostate biopsies with AI algorithm review, 24-hour screening services, and UKAS annual audit services.
- Whole Slide Imaging Scanning Services: Standalone scanning service where client slides are digitized onto removable storage device or hosted in secure image cloud. Also includes MDT and second opinion arrangement services.
- Diagnostic Audits: Independent Investigative Audits and Duty of Care Reviews following Royal College of Pathologists guidelines, providing qualitative and quantitative summary documents for NHS trusts.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Flat fee structure covering all services |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
LDPath product offering
Product offeringCore offering
LDPath provides digital histopathology reporting services to NHS hospital trusts and private practices, combining whole slide imaging of glass slides with a bespoke Laboratory Information Management System (LIMS) for case tracking and report delivery. The service uses a network of specialist consultant pathologists to deliver rapid 1-2 day histology report turnaround, integrated second opinions, and AI-assisted cancer detection (via the Ibex Galen Prostate partnership) for prostate biopsy diagnosis.
Product overview
LDPath offers a unified digital pathology platform consisting of a core digital pathology reporting platform integrated with specialized service modules. The platform combines whole slide imaging digitization, a bespoke LIMS application for workflow management, and AI-powered diagnostics through the Ibex Galen Prostate partnership. Services are delivered through two main channels: NHS Pathology Services (serving 24 NHS Trusts with NHS LIMS integration) and Private Practice Pathology Services. Additional modules include Diagnostic Audits and standalone Whole Slide Imaging scanning services. The platform enables 1-2 day turnaround times with 94% of cases reported within 72 hours.
Differentiator
Problem solved
Functional benefit
Products and services
- LDPath Digital Pathology Reporting Platform A cloud-based digital pathology reporting platform combining state-of-the-art histology digital imaging with a pathologist-designed reporting solution, providing the largest library of digital pathology images in the UK (over 100TB accumulated since 2014). Enables rapid 1-2 day histology report turnaround and on-demand second opinions from specialists.
- NHS Pathology Services Surgical pathology reporting service for NHS Trusts, providing histopathology expertise with IT connectivity and NHS LIMS integration via the Health and Social Care Network, currently serving 24 NHS Trusts across the UK.
- Private Practice Pathology Services
- AI-Powered Diagnostics (Ibex Galen Prostate) AI-integrated diagnostic workflow using Ibex Medical Analytics' CE-marked Galen Prostate solution for enhanced quality assurance in prostate cancer detection, including primary reporting with AI algorithm review, 24-hour screening services, and discrepancy alerts to pathologists.
- Diagnostic Audits
- Whole Slide Imaging Scanning Service
Companies that use LDPath
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
LDPath technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature4 records
LDPath partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Ibex Medical AnalyticscoreLDPath partnered with Ibex Medical Analytics to integrate AI-powered cancer detection into their digital pathology workflow. This partnership deployed Ibex's CE-Marked Galen Prostate solution, enabling AI algorithm review of prostate biopsies alongside pathologist diagnosis. The integration provides quality assurance with discrepancy alerts and enables 24-hour prostate biopsy screening services. LDPath was the first UK pathology provider to integrate AI into digital pathology workflow.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
LDPath competitors and assessment
Company assessmentEmerging players
- PathAI: AI-driven pathology platform developing diagnostic and drug-development tools for histopathology. Comparable to LDPath's AI roadmap and a potential competitor for AI-enabled cancer detection contracts with NHS trusts and pharmaceutical sponsors.
- Ibex Medical Analytics: AI-powered cancer diagnostics developer and LDPath's technology partner for Galen Prostate. Comparable as a pathology-AI specialist; operates in the same clinical workflow with competing AI products that could be deployed by NHS trusts directly, bypassing LDPath.
- Proscia: Digital pathology software platform enabling AI-powered image analysis and pathology workflows. Comparable to LDPath's digital pathology platform layer; both sell into hospital pathology departments and biopharma, with overlapping AI/digital strategy.
- Paige: AI-native pathology company with FDA-authorized cancer detection products. Comparable to LDPath in AI-augmented cancer diagnostics and represents a potential competitor for AI procurement deals with NHS trusts and large hospital networks.
Direct peers
- Diagnexia: Digital pathology platform providing remote histopathology reporting services to NHS trusts and private clients. Direct competitor to LDPath with similar cloud-based slide hosting, specialist pathologist network, and NHS-focused GTM motion.
- Synlab: Europe's largest medical diagnostics services provider with extensive histopathology capacity. Comparable to LDPath as a multi-country outsourced pathology provider serving both public health systems and private clients with digital workflow integration.
- Source BioScience: Parent company of LDPath following the 2021 £18.5M acquisition. Provides cellular pathology and genomic services that complement LDPath's digital pathology platform, with overlapping histopathology capabilities and shared customer relationships across NHS and pharmaceutical clients.
- Unilabs: Major European clinical diagnostics and pathology provider offering histopathology services across multiple countries. Competes with LDPath in outsourced pathology reporting and operates a similar business model combining specialist pathologists with digital workflow.
Broad incumbents
- Leica Biosystems: Danaher-owned provider of digital pathology hardware, software (Aperio), and laboratory workflow solutions. Comparable to LDPath as an established digital pathology player, though operating more broadly across equipment, reagents, and software.
- Roche Diagnostics (uPath): Global diagnostics incumbent offering the uPath digital pathology software platform alongside companion diagnostic AI. Comparable as an integrated digital pathology solution competing for the same NHS trust and hospital contracts as LDPath, with deeper R&D and distribution resources.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
LDPath social profiles
Digital presenceLDPath compliance and trust
Trust signalCompliance6 records
LDPath financial estimates
Financial estimateRevenue estimate
Valuation estimate
LDPath leadership team
Management profileNumber of profiles
Profiles7 records
LDPath subsidiaries and ownership
Company hierarchySubsidiaries2 records
LDPath funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LDPath M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LDPath
What does LDPath do?
LDPath provides digital histopathology reporting services to NHS hospital trusts and private practices, combining whole slide imaging of glass slides with a bespoke Laboratory Information Management System (LIMS) for case tracking and report delivery. The service uses a network of specialist consultant pathologists to deliver rapid 1-2 day histology report turnaround, integrated second opinions, and AI-assisted cancer detection (via the Ibex Galen Prostate partnership) for prostate biopsy diagnosis.
Is LDPath a public or private company?
LDPath is a private company. It is classified as corporate owned and is currently operating.
When was LDPath founded?
LDPath was founded in 2011. It employs 11 to 50 people.
Where is LDPath based?
LDPath is headquartered in London, United Kingdom, in the Europe region.
How does LDPath make money?
Four revenue lines are on record. Histopathology Reporting Services are the primary driver. The others are AI Diagnostic Services, whole Slide Imaging Scanning Services and diagnostic Audits.
Who are LDPath's main competitors?
Emerging players on record are PathAI, Ibex Medical Analytics, Proscia and Paige. Direct peers are Diagnexia, Synlab, Source BioScience and Unilabs. Broad incumbents are Leica Biosystems and Roche Diagnostics (uPath).
Does LDPath have an API?
No public API is recorded for LDPath.
What industry is LDPath in?
LDPath's product category is Digital Pathology Services. Its primary akta.pro industry code is HLAGAFAI, Pathology & Histopathology Services, with a secondary code of HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow. Its NAICS code is 621512 and its SIC code is 8071.